Global Transdermal Skin Patches Market Size, Segmentation, Trends and Growth Analysis Forecast by 2030

Transdermal Skin Patches Market Overview and Analysis:

The Transdermal Skin Patches Market size is currently valued at USD 8.51 billion in 2022, registering a CAGR of 4.87% during the forecast period (2023-2030).

Transdermal skin patches, often simply referred to as transdermal patches, are pharmaceutical or therapeutic delivery systems designed to administer medications, hormones, or other active substances through the skin and into the bloodstream. These patches are typically thin, adhesive-backed, and can be applied directly to the skin's surface. The active ingredient in the patch is slowly released and absorbed through the skin over a specified period, providing a controlled and consistent delivery of the drug or substance.

The increasing advantages of transdermal medicine over oral and ingesting medications and increasing funding and investments in drug development are driving the growth of the studied market.

Segmentation:

The Global Transdermal Skin Patches Market is segmented

By Type :

• Single-layer Drug-in-Adhesive
• Multi-layer Drug-in-Adhesive
• Matrix
• Other Types

Application :

• Pain Relief
• Smoking Reduction
• Cessation Aid
• Overactive Bladder
• Hormonal Therapy
• Other Applications

Geography :

• North America
• Europe
• Asia-Pacific
• Middle East
• Africa
• South America

The report offers the value in USD million for the above segments.

Transdermal Skin Patches Market Latest Trends:

The advancements in adhesive technologies are leading to patches that adhere better to the skin, even during activities like swimming or exercising. Enhanced skin tolerance is crucial to minimize skin irritation. In recent times, transdermal patches for continuous glucose monitoring have gained popularity among individuals with diabetes. These patches provide real-time glucose level data and reduce the need for frequent fingerstick testing. Thus, these latest market trends are contributing to the studied market growth.

Drivers :

Increasing Advantages of Transdermal Medicine Over Oral and Ingested Medications

Transdermal medicine delivery, often in the form of transdermal patches, is gaining prominence in the field of healthcare as a viable alternative to traditional oral and ingested medications. Several advantages associated with transdermal medicine are driving this shift in pharmaceutical administration. Transdermal patches can provide prolonged drug delivery, offering relief or therapeutic effect over an extended period, sometimes up to several days or weeks, reducing the frequency of application. Thus, the market is expected to witness significant growth over the forecast period.

Increasing Funding and Investments in Drug Research

According to data from the Migraine Research Foundation, as of 2021, migraine is an extremely common neurological condition that affects approximately 39 million individuals in the United States and a staggering 1 billion people globally. This makes migraine the third-most prevalent illness worldwide. The high prevalence of migraine underscores the growing demand for effective solutions to alleviate the pain associated with migraine headaches, which, in turn, is driving the growth of the market for migraine relief patches. Furthermore, the market is benefiting from increased efforts by companies to develop innovative pain relief patches. For instance, in November 2021, NEXGEL introduced its MEDAGEL Migraine Relief Patch, which leverages NEXGEL's proprietary hydrogel technology. This patch offers both immediate and long-lasting cooling relief for individuals dealing with migraines, hormonal headaches, and fevers by effectively drawing heat away from the body. These advancements and product launches are significant contributors to the market's growth prospects throughout the forecast period.

Restraints :

Inability of the Skin to Absorb a Range of Active Substance

Transdermal patches have gained recognition as a convenient and effective means of administering medications and active substances through the skin. However, one of the challenges facing the transdermal patch market is the inherent limitation of the skin's ability to absorb a wide range of active substances. Transdermal patches offer numerous advantages in drug delivery, the skin's limited ability to absorb a wide range of active substances poses a substantial challenge to the growth of the transdermal patch market. Thus, the growth of the market is expected to slow down over the forecast period.

COVID-19 Impact on Transdermal Skin Patch Market

The transdermal skin patches market has experienced the profound impact of the COVID-19 outbreak. These patches have gained attention for their ability to facilitate the safe, controlled, and consistent delivery of drugs within a defined microenvironment of the skin. As a result, in the quest to develop a potential vaccine against the novel COVID-19 strain, researchers explored innovative approaches, including the use of small, fingertip-sized skin patches for drug delivery. For example, a noteworthy development emerged in May 2020 when researchers from the University of Pittsburgh Medical Center and the University of Pittsburgh embarked on a project to create a microneedle array (MNA). This fingertip-sized patch featured 400 microscopic needles designed to introduce spike protein fragments into the skin, a novel approach to vaccine delivery. This endeavor exemplifies the adaptability and innovative potential of transdermal patches in addressing critical healthcare challenges, such as the need for effective COVID-19 vaccination methods.

Segmental Analysis :

Pain Relief Segment Expects to Register a High CAGR in the Transdermal Skin Patches Market Over the Forecast Period

The transdermal patches market is poised to witness significant growth in the pain-relief segment over the forecast period. Several factors contribute to the growth of this segment, notably the increasing prevalence of pain-related disorders within the population. Conditions such as diabetic neuropathy, rheumatoid arthritis, osteoarthritis, migraines, and other pain-related ailments have become increasingly common. For instance, a February 2022 article highlighted the widespread issue of back pain, with up to 23% of the global population experiencing chronic low back pain. Additionally, the same source indicated a recurrence rate of 24% to 80% within the target group and lifetime prevalence estimates as high as 84% among adults. Consequently, the growing burden of back pain within the population is expected to drive demand for pain relief patches, thereby boosting the growth of this segment.

Furthermore, data from the Migraine Research Foundation, updated in 2021, revealed the staggering prevalence of migraines as a neurological disorder. Migraine affects approximately 39 million individuals in the United States and an astounding 1 billion people worldwide, making it the third-most prevalent illness on a global scale. This high prevalence underscores the increasing demand for effective patches designed to alleviate the pain associated with migraine headaches. As a result, the market for pain relief patches is expected to experience substantial growth.

Moreover, the market's growth is further accelerated by the increasing activities of companies involved in the development of pain relief patches. An example of this is NEXGEL, which, in November 2021, introduced the MEDAGEL Migraine Relief Patch, leveraging NEXGEL's innovative hydrogel technology. This patch is designed to provide immediate and long-lasting cooling relief for individuals experiencing migraines, hormonal headaches, and fevers by effectively dissipating heat from the body. These advancements and product launches play a pivotal role in propelling the market's growth prospects throughout the forecast period. Thus, due to the above-mentioned reasons the segment is expected to witness significant growth over the forecast period.

Multi-layer Drug-in-Adhesive Segment is Expected to Witness Significant growth Over the Forecast Period

A multi-layer drug-in-adhesive transdermal patch is an advanced pharmaceutical delivery system designed to administer medications through the skin gradually. These patches consist of multiple layers, each serving a specific purpose to ensure controlled drug release and efficient transdermal delivery. The drug matrix contains the active pharmaceutical ingredient (API), which is the medication intended for transdermal delivery. This layer may consist of a reservoir of the drug, a drug-in-adhesive matrix, or drug-containing micro/nanoparticles embedded within the adhesive layer. The drug matrix is designed to control the release rate of the drug. As a result, the segment is expected to witness significant growth over the forecast period.

North America Region is Expected to Witness Significant Growth Over the Forecast Period

North America is poised for substantial growth in the transdermal patches market in the coming years. This growth can be attributed to several key factors, including the presence of major industry players and a well-established healthcare infrastructure. Additionally, the region benefits from increasing government initiatives and a growing number of research partnerships, all contributing to the expansion of the market. Within North America, the United States is expected to dominate the transdermal patches market. This is primarily due to the presence of supportive healthcare policies, a substantial population dealing with chronic pain and other long-term medical conditions, and a highly developed healthcare sector. Notably, the rising number of smokers in the region is expected to drive the demand for nicotine transdermal patches. Recent data from the CDC in March 2022 indicated that a significant portion of high school and middle school students in the United States had used tobacco products, with electronic cigarettes being the most commonly used product. In Canada, despite public health education and preventive efforts, about 15% of the population continues to smoke, leading to preventable diseases and deaths. The advent of innovative drug delivery methods like transdermal patches has gained traction, contributing to market growth. Furthermore, the rising incidence of cancers, including breast and prostate cancer, is expected to significantly accelerate market growth. For instance, data from the GLOBOCAN 2020 report highlighted a substantial number of cancer cases in Mexico, with breast and prostate cancers being the most prevalent. This trend is projected to continue, necessitating transdermal patches with drug nanoparticles to manage pain from cancer therapy.

Government and organizational initiatives in Mexico aimed at preventing smoking are likely to bolster the market's growth. For example, a campaign launched in April 2022 in Cancun targeted U.S. visitors and aimed to raise awareness among international tourists about the harmful effects of smoking.

Moreover, the market's growth is further driven by product launches and business strategies adopted by companies to maintain their market positions. For instance, BASF introduced the 'Sacred Patch,' an active skincare ingredient designed to enhance emotional well-being. Similarly, in 2020, Amneal Pharmaceuticals Inc. received approval from the USFDA for a generic version of the Butrans Transdermal System. In conclusion, the transdermal patches market in North America is poised for significant growth in the forecast period, driven by various factors, including the high prevalence of pain-related disorders, initiatives to combat smoking, and the need for innovative drug delivery systems to manage chronic conditions and cancer therapy-related pain. The continued efforts of both governments and companies in this region are expected to further fuel market expansion.

Transdermal Skin Patches Market Competitive Landscape:

The transdermal skin patches market is moderately competitive. The key players are focused on adopting product innovations, product launches and approvals, R&D investment for advancements in transdermal patches, and mergers and acquisitions as their developmental strategies to sustain the competitive market environment. Some major companies in the market are:

• Teva Pharmaceuticals USA Inc.
• Novartis AG
• Teikoku Pharma USA Inc.
• Mylan Inc.
• 3M

Recent Developments:

1. In September 2022, Corium launched its Adlarity (donepezil transdermal system) for prescription use in the US Adlarity, a once-weekly patch, delivers consistent doses of donepezil through the skin. It could treat patients with mild, moderate, or severe dementia of Alzheimer’s type

2. In April 2022, Luye Pharma Group announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) had accepted the Marketing Authorization Application (MAA) for the company’s investigational Rivastigmine Twice Weekly Transdermal Patch that was indicated for treating Alzheimer's disease of mild to moderate symptoms.

Frequently Asked Questions (FAQ) :

Q1. What is the current Transdermal Skin Patches Market size?

Q2. At what CAGR is the market projected to grow within the forecast period?

Q3. Which region has the largest share of the Transdermal Skin Patches Market? What are the largest region's market size and growth rate?

Q4. What segments are covered in the Transdermal Skin Patches Market Report?